Doug Melton | |
---|---|
Born | Douglas A. Melton |
Nationality | American |
Alma mater | |
Known for | Research on cure for type 1 diabetes |
Awards |
|
Scientific career | |
Fields | |
Institutions | |
Thesis | The expression of transfer RNA genes to other DNAs microinjected into Xenopus oocytes (1979) |
Doctoral advisor | John Gurdon[1] |
Notable students |
|
Website |
Douglas A. Melton is an American medical researcher who is the Xander University Professor at Harvard University, and was an investigator at the Howard Hughes Medical Institute until 2022.[5] Melton serves as the co-director of the Harvard Stem Cell Institute and was the first co-chairman (with David Scadden) of the Harvard University Department of Stem Cell and Regenerative Biology. Melton is the founder of several biotech companies including Gilead Sciences, Ontogeny (now Curis), iPierian (now True North Therapeutics Archived 2017-06-29 at the Wayback Machine), and Semma Therapeutics. Melton holds membership in the National Academy of the Sciences,[6] the American Academy of Arts and Sciences, and is a founding member of the International Society for Stem Cell Research.[7]